Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Receives $68.67 Average Target Price from Brokerages

Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) has been given a consensus rating of “Moderate Buy” by the eleven ratings firms that are presently covering the firm, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell recommendation, eight have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $68.6667.

Several equities analysts have recently commented on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Structure Therapeutics in a research report on Wednesday, October 8th. Stifel Nicolaus set a $50.00 target price on shares of Structure Therapeutics in a research note on Tuesday. Citigroup reaffirmed a “market outperform” rating on shares of Structure Therapeutics in a report on Monday, November 24th. Guggenheim reduced their price objective on Structure Therapeutics from $92.00 to $90.00 and set a “buy” rating for the company in a research report on Thursday, August 7th. Finally, JMP Securities lowered their target price on Structure Therapeutics from $89.00 to $87.00 and set a “market outperform” rating on the stock in a research report on Thursday, August 7th.

Structure Therapeutics Stock Down 7.1%

Shares of GPCR stock opened at $32.12 on Friday. The company has a market cap of $1.86 billion, a P/E ratio of -26.33 and a beta of -1.64. The business has a 50 day moving average of $30.92 and a two-hundred day moving average of $24.10. Structure Therapeutics has a 52 week low of $13.22 and a 52 week high of $40.29.

Structure Therapeutics (NASDAQ:GPCR) last released its quarterly earnings data on Thursday, November 6th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.01). Analysts expect that Structure Therapeutics will post -0.82 EPS for the current fiscal year.

Institutional Investors Weigh In On Structure Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of GPCR. PNC Financial Services Group Inc. increased its holdings in shares of Structure Therapeutics by 9.4% in the third quarter. PNC Financial Services Group Inc. now owns 4,828 shares of the company’s stock valued at $135,000 after buying an additional 413 shares in the last quarter. Assetmark Inc. raised its position in shares of Structure Therapeutics by 39.9% during the second quarter. Assetmark Inc. now owns 2,877 shares of the company’s stock worth $60,000 after purchasing an additional 820 shares during the period. EverSource Wealth Advisors LLC raised its position in shares of Structure Therapeutics by 530.0% during the third quarter. EverSource Wealth Advisors LLC now owns 1,071 shares of the company’s stock worth $30,000 after purchasing an additional 901 shares during the period. ANTIPODES PARTNERS Ltd lifted its holdings in shares of Structure Therapeutics by 39.1% during the third quarter. ANTIPODES PARTNERS Ltd now owns 4,078 shares of the company’s stock valued at $114,000 after purchasing an additional 1,146 shares during the last quarter. Finally, State of Wyoming acquired a new position in shares of Structure Therapeutics in the 2nd quarter valued at $28,000. 91.78% of the stock is currently owned by institutional investors.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.